

Min-Han Tan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2703185/publications.pdf>

Version: 2024-02-01

88
papers

8,346
citations

101543

36
h-index

56724

83
g-index

91
all docs

91
docs citations

91
times ranked

13401
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma. <i>Cancer Communications</i> , 2020, 40, 564-585.	9.2	49
2	Assessment of PARP4 as a candidate breast cancer susceptibility gene. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 145-153.	2.5	8
3	Size-Based Enrichment Technologies for Non-cancerous Tumor-Derived Cells in Blood. <i>Trends in Biotechnology</i> , 2018, 36, 511-522.	9.3	24
4	Evaluation of three polygenic risk score models for the prediction of breast cancer risk in Singapore Chinese. <i>Oncotarget</i> , 2018, 9, 12796-12804.	1.8	19
5	World Cancer Day. <i>Annals of the Academy of Medicine, Singapore</i> , 2018, 47, 88-89.	0.4	0
6	The Issue of Tissue in Molecular Stratification. <i>Oncologist</i> , 2017, 22, 1560-1560.	3.7	0
7	Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma. <i>Scientific Reports</i> , 2017, 7, 7342.	3.3	46
8	Identification of Novel Breast Cancer Risk Loci. <i>Cancer Research</i> , 2017, 77, 5428-5437.	0.9	12
9	Differential radiologic characteristics of renal tumours on multiphase computed tomography. <i>Singapore Medical Journal</i> , 2017, 58, 262-266.	0.6	8
10	Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy. <i>Scientific Reports</i> , 2016, 6, 13.	3.3	97
11	Circulating Tumor Cells and Circulating Tumor DNA in Colorectal Cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 181-194.	0.7	1
12	Tumor-derived circulating endothelial cell clusters in colorectal cancer. <i>Science Translational Medicine</i> , 2016, 8, 345ra89.	12.4	92
13	Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore. <i>Npj Genomic Medicine</i> , 2016, 1, 15003.	3.8	44
14	Clinical and molecular characteristics of East Asian patients with von Hippel-Lindau syndrome. <i>Chinese Journal of Cancer</i> , 2016, 35, 79.	4.9	6
15	Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation. <i>Chinese Journal of Cancer</i> , 2016, 35, 10.	4.9	43
16	Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 168-175.	1.9	15
17	Doubling Down on mTOR Inhibition: Harnessing ZEBRA for Insights. <i>European Urology</i> , 2016, 69, 457-459.	1.9	3
18	Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0134102.	2.5	25

#	ARTICLE	IF	CITATIONS
19	Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population. PLoS ONE, 2015, 10, e0134408.	2.5	15
20	Noninvasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. Molecular Oncology, 2015, 9, 850-860.	4.6	59
21	Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. Targeted Oncology, 2015, 10, 429-437.	3.6	27
22	Reproductive factors and lung cancer risk among women in the Singapore Breast Cancer Screening Project. Lung Cancer, 2015, 90, 499-508.	2.0	18
23	Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. Clinical Genitourinary Cancer, 2015, 13, 150-155.	1.9	10
24	Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore. Clinical Genitourinary Cancer, 2015, 13, e285-e295.	1.9	21
25	CD117 expression in breast phyllodes tumors correlates with adverse pathologic parameters and reduced survival. Modern Pathology, 2015, 28, 352-358.	5.5	21
26	A Multigene Assay Identifying Distinct Prognostic Subtypes of Clear Cell Renal Cell Carcinoma with Differential Response to Tyrosine Kinase Inhibition. European Urology, 2015, 67, 17-20.	1.9	24
27	The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma. PLoS ONE, 2015, 10, e0118658.	2.5	46
28	Fumarate Hydratase-deficient Cell Line NCCFH1 as a New In Vitro Model of Hereditary Papillary Renal Cell Carcinoma Type 2. Anticancer Research, 2015, 35, 6639-53.	1.1	14
29	The Singapore Cancer Network (SCAN) Guidelines: A New Beginning. Annals of the Academy of Medicine, Singapore, 2015, 44, 358-9.	0.4	0
30	Targeted therapy for renal cell carcinoma: The next lap. Journal of Carcinogenesis, 2014, 13, 3.	2.5	24
31	RE: Cowden Syndrome and PTEN Hamartoma Tumor Syndrome: Systematic Review and Revised Diagnostic Criteria. Journal of the National Cancer Institute, 2014, 106, dju130.	6.3	9
32	Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. Clinical Genitourinary Cancer, 2014, 12, 354-358.	1.9	26
33	Potential genetic anticipation in hereditary leiomyomatosis-renal cell cancer (HLRCC). Familial Cancer, 2014, 13, 281-289.	1.9	20
34	Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation. Cancer Chemotherapy and Pharmacology, 2014, 73, 381-388.	2.3	16
35	Utility of the Singapore nomogram for predicting recurrence-free survival in Japanese women with breast phyllodes tumours. Journal of Clinical Pathology, 2014, 67, 748-750.	2.0	23
36	Phenformin-loaded polymeric micelles for targeting both cancer cells and cancer stem cells in vitro and in vivo. Biomaterials, 2014, 35, 9177-9186.	11.4	44

#	ARTICLE	IF	CITATIONS
37	Novel genetic aberrations in breast phyllodes tumours: comparison between prognostically distinct groups. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 635-645.	2.5	28
38	The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. <i>European Urology</i> , 2014, 65, 723-730.	1.9	69
39	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e127-e131.	1.9	25
40	Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. <i>European Urology</i> , 2014, 65, 1086-1092.	1.9	71
41	Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. <i>Cancer</i> , 2013, 119, 313-324.	4.1	43
42	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. <i>Targeted Oncology</i> , 2013, 8, 203-209.	3.6	47
43	Metastatic non-“clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. <i>Cancer</i> , 2013, 119, 2999-3006.	4.1	189
44	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. <i>Lancet Oncology</i> , The, 2013, 14, 141-148.	10.7	808
45	8q24 and 17q Prostate cancer susceptibility loci in a multiethnic Asian cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1553-1560.	1.6	21
46	Label-free isolation of circulating tumor cells in microfluidic devices: Current research and perspectives. <i>Biomicrofluidics</i> , 2013, 7, 11810.	2.4	96
47	Predictive models for the practical management of renal cell carcinoma. <i>Nature Reviews Urology</i> , 2012, 9, 73-84.	3.8	13
48	Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. <i>Journal of Clinical Pathology</i> , 2012, 65, 69-76.	2.0	220
49	Lifetime Cancer Risks of PTEN Mutation Carriers-Response. <i>Clinical Cancer Research</i> , 2012, 18, 4214-4214.	7.0	0
50	Lifetime Cancer Risks in Individuals with Germline <i>PTEN</i> Mutations. <i>Clinical Cancer Research</i> , 2012, 18, 400-407.	7.0	738
51	Exploring the Benefits of Early Access to Palliative Care in Advanced Lung Cancer: Living Better, Living Longer, or Both?. <i>Journal of Clinical Oncology</i> , 2012, 30, 2163-2164.	1.6	1
52	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. <i>Lancet Oncology</i> , The, 2012, 13, 927-935.	10.7	112
53	Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012. <i>Lancet Oncology</i> , The, 2012, 13, e482-e491.	10.7	30
54	Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 849-858.	2.5	45

#	ARTICLE	IF	CITATIONS
55	Vascular endothelial growth factor (VEGF) therapy in metastatic renal cell carcinoma (mRCC): Differences between Asian and non-Asian patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 451-451.	1.6	1
56	Testicular microlithiasis: recent advances in understanding and management. <i>Nature Reviews Urology</i> , 2011, 8, 153-163.	3.8	36
57	Papillary renal cell carcinoma with metastatic laparoscopic port site and vaginal involvement: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 131.	0.8	2
58	An Antioxidant Response Phenotype Shared between Hereditary and Sporadic Type 2 Papillary Renal Cell Carcinoma. <i>Cancer Cell</i> , 2011, 20, 511-523.	16.8	347
59	A Clinical Scoring System for Selection of Patients for PTEN Mutation Testing Is Proposed on the Basis of a Prospective Study of 3042 Proband. <i>American Journal of Human Genetics</i> , 2011, 88, 42-56.	6.2	332
60	'Prechronous' metastasis in clear cell renal cell carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 181.	0.8	3
61	Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. <i>Cancer</i> , 2011, 117, 2637-2642.	4.1	74
62	The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma. <i>Cancer</i> , 2011, 117, 5314-5324.	4.1	42
63	Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. <i>Journal of Medical Genetics</i> , 2011, 48, 226-234.	3.2	116
64	Nasal metastases from renal cell carcinoma are associated with Memorial Sloan-Kettering Cancer Center poor-prognosis classification. <i>Chinese Journal of Cancer</i> , 2011, 30, 144-148.	4.9	12
65	Stage T1N0M0 renal cell carcinoma: the prognosis in Asian patients. <i>Chinese Journal of Cancer</i> , 2011, 30, 772-778.	4.9	9
66	Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. <i>BMC Cancer</i> , 2010, 10, 196.	2.6	86
67	Association Between Being Underweight and Outcomes in Breast Cancer: Alternative Explanations. <i>Journal of Clinical Oncology</i> , 2010, 28, e177-e177.	1.6	1
68	Comparison of the UCLA Integrated Staging System and the Leibovich Score in Survival Prediction for Patients With Nonmetastatic Clear Cell Renal Cell Carcinoma. <i>Urology</i> , 2010, 75, 1365-1370.e3.	1.0	36
69	Transient bilateral abducens neuropathy with post-tetanic facilitation and acute hypokalemia associated with oxaliplatin: a case report. <i>Journal of Medical Case Reports</i> , 2010, 4, 36.	0.8	6
70	An association between transient hypokalemia and severe acute oxaliplatin-related toxicity predominantly in women. <i>Acta Oncologica</i> , 2010, 49, 515-517.	1.8	17
71	A unique pair of monozygotic twins with concordant clear cell renal cell carcinoma: a case report. <i>Annals of the Academy of Medicine, Singapore</i> , 2010, 39, 61-3.	0.4	0
72	A multimodality approach to reversible paraneoplastic encephalitis associated with ovarian teratomas. <i>Acta Oncologica</i> , 2009, 48, 1079-1082.	1.8	1

#	ARTICLE	IF	CITATIONS
73	Race to Report: Are Vascular Endothelial Growth Factor Genetic Polymorphisms Associated With Outcome in Advanced Breast Cancer Patients Treated With Paclitaxel Plus Bevacizumab?. <i>Journal of Clinical Oncology</i> , 2009, 27, 1342-1342.	1.6	2
74	Gastrointestinal stromal tumour in the elderly. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 70, 256-261.	4.4	14
75	A unique case of spontaneous regression of metastatic papillary renal cell carcinoma: a case report. <i>Cases Journal</i> , 2009, 2, 7769.	0.4	6
76	Identification of copy number alterations and its association with pathological features in clear cell and papillary RCC. <i>Cancer Letters</i> , 2008, 272, 260-267.	7.2	27
77	Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab. <i>Leukemia and Lymphoma</i> , 2008, 49, 462-469.	1.3	95
78	Somatic Pairing of Chromosome 19 in Renal Oncocytoma Is Associated with Deregulated ELGN2-Mediated Oxygen-Sensing Response. <i>PLoS Genetics</i> , 2008, 4, e1000176.	3.5	58
79	The Tao of bao: a randomised controlled trial examining the effect of steamed bun consumption on night-call inpatient course and mortality. <i>Annals of the Academy of Medicine, Singapore</i> , 2008, 37, 255-3.	0.4	1
80	Two Distinct Types of Blood Vessels in Clear Cell Renal Cell Carcinoma Have Contrasting Prognostic Implications. <i>Clinical Cancer Research</i> , 2007, 13, 161-169.	7.0	81
81	Patterns of somatic mutation in human cancer genomes. <i>Nature</i> , 2007, 446, 153-158.	27.8	2,802
82	Parafibromin inhibits cancer cell growth and causes G1 phase arrest. <i>Biochemical and Biophysical Research Communications</i> , 2006, 350, 17-24.	2.1	84
83	A Molecular Classification of Papillary Renal Cell Carcinoma. <i>Cancer Research</i> , 2005, 65, 5628-5637.	0.9	226
84	Gene expression profiling of renal cell carcinoma and clinical implications. <i>Urology</i> , 2005, 65, 231-237.	1.0	5
85	Loss of Parafibromin Immunoreactivity Is a Distinguishing Feature of Parathyroid Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 6629-6637.	7.0	223
86	Gene Expression of Parathyroid Tumors. <i>Cancer Research</i> , 2004, 64, 7405-7411.	0.9	96
87	Gene Expression Profiling of Renal Cell Carcinoma: Fig. 1.. <i>Clinical Cancer Research</i> , 2004, 10, 6315S-6321S.	7.0	39
88	Post-encephalitic segmental dystonia with apraxia of eyelid opening. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 173-175.	2.2	1